NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Interventional procedure overview of radiofrequency cold ablation for respiratory papillomatosis

Treating papillomas in the throat and airways using electrical energy

Respiratory papillomatosis is a condition in which non-cancerous wart-like growths called papillomas grow in the throat or airways. It affects both children and adults and can causes voice changes and shortness of breath. The condition is caused by the human papilloma virus and can keep coming back after treatment. This procedure aims to dissolve or shrink the papillomas using an electric current. The procedure uses a lower temperature than other treatments, with minimal heat damage to surrounding healthy tissue.

Introduction

The National Institute for Health and Clinical Excellence (NICE) has prepared this overview to help members of the Interventional Procedures Advisory Committee (IPAC) make recommendations about the safety and efficacy of an interventional procedure. It is based on a rapid review of the medical literature and specialist opinion. It should not be regarded as a definitive assessment of the procedure.

Date prepared

This overview was prepared in March 2012.

Procedure name

Radiofrequency cold ablation for respiratory papillomatosis

Specialty societies

- British Association of Otorhinolaryngologists, Head and Neck Surgeons (ENT UK)
- British Association of Paediatric Otolaryngologists

Description

Indications and current treatment

Respiratory papillomatosis is a condition characterised by benign papillomatous (wart-like) growths in the respiratory tract (larynx, trachea and rarely lungs). It can affect both children and adults, causing voice changes and airway obstruction. The condition tends to recur after treatment, requiring multiple procedures to control growth of the lesions. In such cases, the condition is known as recurrent respiratory papillomatosis.

Surgical therapy is aimed at complete removal of papillomas, while preserving normal structures, maintaining airway patency and improving voice quality. Treatment options include repeated surgical debulking of the papillomas, by cold steel dissection, suction diathermy, cryotherapy, carbon dioxide (CO₂) or other lasers, or microdebridement. Any of these may be followed by systemic administration or direct injection of antiviral agents (for example, cidofovir) into the resection sites, with the aim of reducing the frequency of reoperative surgery. Tracheostomy may be needed if significant airway obstruction occurs. No single treatment method has been shown to be effective in eradicating recurrent respiratory papillomatosis.

Radiofrequency cold ablation (commonly known as coblation) uses controlled energy delivery to operate at the relatively low temperature of 60-65°C. This aims to reduce surrounding tissue damage and postoperative pain and to avoid seeding of viral particles during the thermal vaporisation process.

What the procedure involves

Radiofrequency cold ablation involves passing a radiofrequency bipolar electrical current through a medium of normal saline. This produces a plasma field of sodium ions that dissects the tissue by disrupting intercellular bonds, leading to tissue vaporisation and coagulation. Radiofrequency cold ablation heats tissue to only 60–65°C, which may produce less postoperative pain and damage to surrounding structures than conventional diathermy.

The procedure is usually done with the patient under general anaesthesia. Conventional microlaryngoscopy techniques allow introduction of a single-use radiofrequency probe into the lumen of the larvnx and trachea.

Once the probe tip is in contact with the papilloma, it is activated to produce controlled tissue ablation of individual lesions, together with haemostasis and suction.

Steroids and antibiotics may be given after the procedure to reduce inflammation and the risk of infection.

Clinical assessment tools

Respiratory papillomatosis is difficult to stage. One of the more accepted scoring methods is the Derkay system, in which the surgeon assigns a score of 0–3 to each site in the aero-digestive tract (0 = absent, 1 = surface lesion, 2 = raised lesion and 3 = bulky lesion). A composite score is generated by summing the score at each involved site.

Literature review

Rapid review of literature

The medical literature was searched to identify studies and reviews relevant to radiofrequency cold ablation for respiratory papillomatosis. Searches were conducted of the following databases, covering the period from their commencement to 28 March 2012: MEDLINE, PREMEDLINE, EMBASE, Cochrane Library and other databases. Trial registries and the Internet were also searched. No language restriction was applied to the searches (see appendix C for details of search strategy). Relevant published studies identified during consultation or resolution that are published after this date may also be considered for inclusion.

The following selection criteria (table 1) were applied to the abstracts identified by the literature search. Where selection criteria could not be determined from the abstracts the full paper was retrieved.

Table 1 Inclusion criteria for identification of relevant studies

Characteristic	Criteria
Publication type	Clinical studies were included. Emphasis was placed on identifying good quality studies.
	Abstracts were excluded where no clinical outcomes were reported, or where the paper was a review, editorial, or a laboratory or animal study.
	Conference abstracts were also excluded because of the difficulty of appraising study methodology, unless they reported specific adverse events that were not available in the published literature.
Patient	Patients with respiratory papillomatosis.
Intervention/test	Radiofrequency cold ablation.
Outcome	Articles were retrieved if the abstract contained information relevant to the safety and/or efficacy.
Language	Non-English-language articles were excluded unless they were thought to add substantively to the English-language evidence base.

List of studies included in the overview

This overview is based on 32 patients from 5 case series and 1 case report.

Table 2 Summary of key efficacy and safety findings on radiofrequency cold ablation for respiratory papillomatosis

Study details	Key efficacy findings	Key safety findings	Comments
She (2011) ¹	Number of patients analysed: 18	There was no postoperative bleeding or other complications.	Abstract only. Full- text in Chinese
Case series	Recurrence of respiratory papillomas		language.
China Recruitment period: 2008-10	88.9% (16/18) patients had no recurrence during follow-up. Recurrence occurred in 11.1% (2/18) of patients, 1 occurred 4 months	The volumes of blood loss during surgery varied from 1–10 ml; 2 ml was the average.	Follow-up issues: • Unclear what assessment was
Study population: Adult patients with laryngeal	and the other 8 months after the procedure. Both were retreated by the same procedure and followed up for 4 months and 12 months,	Safety findings identified in Chinese language full-text	carried out during follow-up.
papilloma	respectively. Recurrence occurred again in 1 patient.	Tissue scarring	
n = 18 (14 patients with single laryngeal papilloma and 4 patients with multiple laryngeal papilloma)		Minor scarring around the ablated tissues was reported in all patients.	Study population issues: Unknown from abstract whether
Age: not reported		Appearance of respiratory papillomas at another location	study population
Sex: not reported Patient selection criteria: Not reported		Four months after the procedure, there was no recurrence of respiratory papillomas at the original ablated site in 1 patient, but respiratory papillomas appeared at another location. Radiofrequency cold ablation was repeated with no recurrence at 2 month follow-up.	had respiratory papillomatosis before.
Technique: All patients were treated with Coblator [™] Reflex #7070 under general anaesthesia without tracheotomy.		monurionow-up.	
Follow-up: 18 months (median)			
Conflict of interest/source of funding: Not reported			

Study details	Key efficacy find	dings		Key safety findings	Comments
Carney (2010) ²	Number of patien	ts analysed: 6	3	None reported.	Follow-up issues:
Case series Australia Recruitment period: not	Increase in time procedures com procedures requ	pared with ti	me interval bet	on	 Actual number of years patient received CO₂ laser or radiofrequency cold ablation
reported Study population: Adult	Definition	No. of patients	Reported p-value		treatment was not reported.
patients with advanced laryngotracheal RRP	Modest increase (< 25%	3	Not reported		Study design issues:
n = 6 Age: 34 (median)	increased time interval)				This is a retrospective comparative study.
Sex: 50% male Patient selection criteria: Patients who were treated	Significant increase (> 50% increased time	3	0.0342		comparative study. There could be potential bias in patient selection.
for at least 2 years by CO ₂ laser vaporisation with or without intralesional	interval)				Study population issues:
cidofovir and subsequently treated with radiofrequency cold ablation with or without intralesional cidofovir for a further 2 years.	Other findings After a number of radiofrequency cold ablation resections 1 patient's papillomas became less exophytic, tending to a more sessile appearance, a finding not previously reported for laser procedures.				All patients exhibited marked differences in the severity of their RRP, from advanced laryngeal disease with only solitary tracheal
Technique: All patients were treated under general anaesthesia using jet ventilation. A 0° Hopkins rod endoscope and camera					lesions, to almost complete circumferential papillomas involving most of the trachea with minimal
were used with a Storz C laryngoscope (Storz, Tuttlingen, Germany) to visualise the tracheobronchial lesions. A modified, three-electrode,					 laryngeal disease. Three patients had juvenile onset RRP. It was unclear if the natural history of the

Study details	Key efficacy findings	Key safety findings	Comments
bipolar radiofrequency device (Coblator I; Arthrocare, Sunnyvale, California, USA) was use to ablate papillomas. Before each insertion into the airway, the wand tip was placed in saline gel of create an adequate environment for the radiofrequency cold ablation plasma field. The power level was set to provide 800–1200 J of energy. Papillomas were ablated by placing the tip the wand over the lesions at a 90° angle where	ed of		juvenile and adult onset RRP was different. • Four patients had been treated previously with intralesional cidofovir after lase resection but were regarded as havin no response, although intralesional treatment was also continued in these 4 patients after radiofrequency co ablation. There was
possible to minimise surrounding thermal damage. Follow-up: not reported Conflict of interest/source			uncertainty about the potential impa of intralesional cidofovir on time interval in the long term in patients w have no previous responded to it.
of funding: One author is currently a member of the International Medical Advisory Board of the device manufacturer. He has received funding/sponsorship from the device manufacturer lecture on radiofrequency cold ablation technology sponsored postgraduate meetings.	e n to		Other issues: • The radiofrequence cold ablation deviused was original designed for orthopaedic use.

Study details	Key efficacy find	ings			Key safety findings	Comments
Peters (2011) ³	Number of patient	s analysed: 3			There were no complications.	Follow-up issues:
Case series (3 case	Operative succes	ss				There was no fixed duration of follow-
reports)		Patient 1	Patient 2	Patient 3		up.
USA	Immediately	Denied any	Denied	Patient was		0. 1. 1. 1. 1. 1. 1. 1.
Recruitment period: not reported	after radio frequency	dysphagia or symptoms of	dysphagia, nasopharyngeal	asymptomatic		Study design issues:Only 1 patient was
Study population: patient with recurrent papilloma of the nasopharynx	cold ablation	velo- pharyngeal insufficiency	reflux or globus			reported to have received intra- lesional cidofovir
n = 3 (4 procedures)		(difficulties swallowing or				injection after radiofrequency cold
Age: 52, 55 and 66		speaking)				ablation.
Sex: 67% male	Recurrence of respiratory	A small recurrent	No evidence of recurrence at	No evidence of recurrence		Study population
Patient selection criteria: Endoscopic examination of patient 1 revealed nasopharyngeal multifocal papillomas. Endoscopic examination of patient 2 revealed a 3 cm sessile papilloma on the nasopharyngeal surface of the soft palate. Endoscopic examination of patient 3	papillomatosis	lesion of the right fossa of Rosenmuller (3 mm) was found at about 4 months after initial treatment with radio frequency cold ablation	15-month follow- up	at 17-month follow-up		 One patient had active acquired immune deficiency syndrome.
revealed a 2 cm papilloma on the nasopharyngeal	Management and outcome	Radio				
surface of the soft palate	of recurrent	frequency cold ablation				
near the midline.	respiratory	was repeated				
	papillomatosis	with no				
Technique: patients were	after first radio	evidence of recurrent				
treated with endoscopic	frequency	disease at 2-				
transnasal radiofrequency cold ablation. An	cold ablation	month follow-				
cold ablation. An Arthrocare EVac 70	treatment	up				
Coblator (setting:	Other notes	Patient later				

Abbreviations used: CO ₂ , car	bon dioxide; RRP, recurrent respiratory papillomatosis		
Study details	Key efficacy findings	Key safety findings	Comments
		Key safety findings	Comments

Study details	Key efficacy finding	JS .		Key safety findings		Comments		
Timms (2007) ⁴	Number of patients a	nalysed: 2		Patient 1 (patient pre-		Follow-up issues: • Unclear what		
Case series (2 case	Operative success			Follow-up	Outcome	assessment was		
reports) India and United Kingdom	Patient 1 (patient pre dyspnoea)	sented with severe hoarse	eness and exertional	Immediately after the procedure	The appearance of the larynx was	carried out during follow-up.		
Recruitment period: not reported	Follow-up Immediately after	Outcome The appearance of			normal, with no signs of charring or	Other issues:		
Study population: adult patients with extensive and	the procedure	the larynx was normal.			bleeding. Patient's recovery was uneventful, and no	 There was no forma tool to assess treatment efficacy 		
recurrent laryngeal papillomas	2-month	Patient was found to have good voice			signs of oedema were seen on	for example voice recording analysis.		
n = 2 Age: 38 and 41		and no exertional dyspnoea.			endoscopic examination the	 There was no format statistical 		
Sex: 50% male	6-month	Remained well.			following morning.	comparison of even		
Patient selection criteria: One patient presented with				Patient 2 (patient had extensive papillomas affecting the glottis and supraglottis)		recurrence before and after the procedure. • A mucosal wave is		
severe hoarseness and				Follow-up	Outcome	the ripple that		
exertional dyspnoea. She had extensive papillomas on both vocal folds. The other patient had extensive				Immediately after the procedure	Patient discharged on same day of procedure with no complications.	passes along a normal vocal cord during phonation. It is changed when		
papillomas affecting the glottis and supraglottis. Both patients had previously received surgical treatment,				4-month	A mucosal wave was seen bilaterally at laryngeal stroboscopy.	vocal fold scar is present. Vocal fold scar causes the mucosal wave to be irregular and/or		
including cold steel surgery and laser techniques for their respiratory papillomatosis.						reduced in both speed and extent of movement (amplitude).		
Technique: A microlaryngeal tube was used in 1 patient. An expandable laser								

Abbreviations used: CO ₂ , carbon dioxide; RRP, recurrent respiratory papillomatosis							
Study details	Key efficacy findings	Key safety findings	Comments				
laryngoscope was used to							
gain adequate exposure of							
the larynx in the other							
patient. The procedures were performed in the two							
patients using different							
wands, an Evac 70 wand							
(Arthrocare, Sunnyvale,							
California, USA) and an EIC070 wand (Arthrocare).							
No antibiotics or steroids							
were used in either patient.							
Follow-up: up to 6 months							
Conflict of interest/source							
of funding: None							

Study details	Key efficacy fin	dings			Key safety finding	js –		Comments
Psaltis (2003) ⁵	Number of patier	nts analysed: 2			Patient 1			Follow-up issues:
Case series (2 case reports)	Disease recurrence Patient 1				Treatment received	CO ₂ laser (treatment received	Radio frequency cold	Duration of follow-up not reported.Unclear how many
Australia Recruitment period: not reported	Treatment received	CO ₂ laser (treatment received	Radiofrequency cold ablation			before radio frequency cold ablation)	ablation	times radiofrequency cold ablation was repeated.
Study population: Adult patients with advanced laryngotracheal		before radio frequency cold ablation)			Complications	Scarring of both cords and posterior inter-arytenoid	None reported	Study design issues: Patient 2 was
papillomatosis. Both patients had juvenile onset RRP diagnosed in their infant years	their treatments received		space and anterior and posterior		subsequently treated with a combination of			
n = 2	Location of papillomas	Larynx, nasal septum and	Superior trachea and supraglottic			glottis webs; patient developed		radiofrequency cold ablation and CO ₂
Age: 25 and 26 Sex: 100% male	treated	upper trachea (up to 4 cm below the vocal cord)	trachea			bronchospasm resulting in 1 treatment		laser. Thus, treatment effectiveness must not be attributed
Patient selection criteria: Both patients had undergone multiple	Operative success immediately	Not reported	The lower trachea and main bronchi appeared clear of			episode being abandoned		only to radiofrequency cold ablation.
previous treatments to their airway with CO ₂ laser.	after the procedure		papillomas		Patient 2	T	T	Other issues:
Technique: Both patients were treated under general anaesthesia and oxygenated using jet ventilation. A long 0-degree Hopkin's Rod endoscope through a Storz C laryngoscope was used to provide visualisation of the	Treatment interval	Approximately 3 months	Subsequent procedures demonstrated reduction in disease recurrence and an extended time period between ablation sessions		Treatment received	CO ₂ laser (treatment received before radio frequency cold ablation)	Radio frequency cold ablation for proximal lesions and CO ₂ laser for distal lesions	 Actual treatment interval between subsequent radiofrequency cold ablation procedures was not reported. The radiofrequency cold ablation device used for both patients was
lesions and a modified Arthrocare orthopaedic 3- electrode probe					Complications	Bilateral pneumo-	None reported	originally designed for orthopaedic use in the ablation of

Study details	Key efficacy find	lings		Key safety findings		Comments
radiofrequency ablation device (coblator) was used to ablate the papillomas. Before each insertion into the airway, the wand tip was placed in saline to ensure the formation of a plasma conduction field. With the controller panel set to a power level between two and four (providing 800–1200 J of energy), the tip of the wand was placed at a 90-degree angle to the papillomas to avoid collateral mucosal damage. Lesions were ablated until the underlying submucosa came into view. The distal lesions that could not be reached by the coblator TM were ablated using the CO ₂ laser bronchoscope. Follow-up: not reported Conflict of interest/source of funding: not reported	Patient 2 Treatment received	CO ₂ laser (treatment received before radio frequency cold ablation)	Radio frequency cold ablation for proximal lesions and CO ₂ laser for distal lesions Not reported	thoraces proximal tracheal strictures delayed bronchos and an asystolic cardiac a	spasm	knee me only read 5 cm bel vocal co cannot b ablate pa the dista trachea.
	treatments received Location of papillomas	Widespread, from base of the epiglottis to the entrance of the right main bronchus.	Massive circumferential papillomas in trachea (< 10% of the lumen visible)		appearance of trachea were to and after the procedures we presented in the paper. The papillomas appeared to habeen removed this is subjective analysis based	
	Treatment interval Treatment effectiveness	Not reported	Subsequent procedures demonstrated a reduction in papilloma regrowth			

Study details	rbon dioxide; RRP, recurrent respiratory papillomatosis Key efficacy findings	Key safety findings	Comments
Rachmanidou (2011) ⁶	Number of patients analysed: 1	There was minimal bleeding during the procedure.	Study design issues: The authors
Case report	Recurrence of respiratory papillomatosis		commented that the
United Kingdom	No sign of recurrence during follow-up at 3 and 18 months.		EIC 7070 laryngeal
Recruitment period: not			wand would have been more suitable
reported	Voice quality		but was not
Study population: paediatric patient with laryngeal papillomatosis	Dramatic improvement (with additional assistance from speech therapy sessions).		available for the procedure. This wand is slimmer
n = 1			(4 mm in diameter),
Age: 32 months			longer (25 cm in
Sex: female			length) and has a 30° bend at its
			distal tip. The
Patient selection criteria:			malleable tip design
paediatric patient with			provides easier access to the
hoarse cry and very croaky			anterior
voice since birth, presenting with a large			commissure,
laryngeal papilloma			together with
occupying the anterior			optimal visibility for
commissure and the			the surgeon.
anterior thirds of both vocal			Other issues:
folds. Derkay staging of			This case report
lesion score: 12.			involves the use of
			radiofrequency cold ablation for de novo
Technique: The			respiratory
papillomatous lesion was			papillomatosis.
excised using an Evac 70Xtra wand (Arthrocare,			A formal tool to
USA). Saline-soaked			assess voice quality
neuropatties were used in			was not defined,
the subglottis to prevent			potentially subjective
distal airway seeding of			measures were used. There is thus
papilloma lesions. The			the potential for
lesion was ablated at a			biased assessment.
setting of 7 and a			2.2002 2000001110111.

Abbreviations used: CO ₂ , ca	Abbreviations used: CO ₂ , carbon dioxide; RRP, recurrent respiratory papillomatosis							
Study details	Key efficacy findings	Key safety findings	Comments					
coagulation setting of 3.								
Saline irrigation and suction were used								
throughout the operation.								
Follow-up: 18 months								
· · · · · · · · · · · · · · · · · · ·								
Conflict of interest/source								
of funding: none declared								

Efficacy

Recurrence of respiratory papillomatosis

In a case series of 3 adult patients with recurrent papillomas of the nasopharynx, only 1 patient had a recurrent lesion at 4-month follow-up, which was successfully re-excised with endoscopic transnasal radiofrequency cold ablation³.

A case series reported 'reduced disease recurrence' (no further details provided) in 2 adult patients with juvenile-onset recurrent respiratory papillomatosis who had previously been treated repeatedly by CO₂ laser ablation; 1 was treated by radiofrequency cold ablation treatment alone and 1 by radiofrequency cold ablation together with CO₂ laser ablation⁵.

In a case report of 1 paediatric patient with a large de novo laryngeal papilloma treated by radiofrequency cold ablation alone, there was no sign of recurrence at 18-month follow-up⁶.

Interval between treatment sessions

In a case series of 6 adult patients with advanced laryngotracheal recurrent respiratory papillomatosis who had previously received at least 2 years of treatment by CO₂ laser ablation followed by at least 2 years of treatment by radiofrequency cold ablation, there was a significant increase (>50%) in the interval between treatments in 3 patients when radiofrequency cold ablation was introduced (p=0.03) and a modest increase (<25%) in the interval between treatments in the other 3 patients (p value not reported)².

In the case series of 2 adult patients, the interval between ablation sessions was increased in 1 patient who was initially treated by CO₂ laser ablation before being subsequently treated with radiofrequency cold ablation (actual interval between procedures not reported)⁵.

Voice quality

In another case series of 2 adult patients with extensive and recurrent laryngeal papillomas, 1 patient who presented with severe hoarseness and exertional dyspnoea was found to have a good voice with no exertional dyspnoea at 2-month follow-up (no formal assessment of voice quality reported)⁴. This patient remained well at 6-month follow-up. No results were reported for the other patient who presented with extensive papillomas affecting the glottis and supraglottis.

In the case report of 1 paediatric patient, a dramatic improvement in voice quality was observed, although the patient also had speech therapy (no formal assessment of voice quality reported)⁶.

Safety

Tissue scarring

Minor scarring around the ablated tissues was reported in all patients in the case series of 18 patients (method of assessment of scarring not described)¹.

Appearance of respiratory papillomas at another location

Respiratory papillomas appeared at a new location 4 months after radiofrequency cold ablation in 1 patient in the case series of 18 patients¹. The procedure was repeated with no further recurrence at 2-month follow-up.

Other findings

There was minimal bleeding during the procedure in the case report of 1 paediatric patient⁶.

Validity and generalisability of the studies

- The studies used different devices, some of which were modified devices originally indicated for orthopaedic procedures.
- Avoiding damage to surrounding tissue is highly dependent on the technique and skills of the surgeon performing the procedure to ensure controlled manoeuvre of the radiofrequency cold ablation device.
- The natural history of juvenile-onset and adult-onset recurrent respiratory papillomatosis might differ. The studies presented in this overview are mostly case series or case reports with no control arm.

Existing assessments of this procedure

 Aetna, a health insurer in the USA, in its Clinical Policy Bulletin: CoblationTM Non-thermal Volumetric Tissue Reduction (Number: 0475) states:

'Aetna considers CoblationTM non-thermal volumetric tissue reduction experimental and investigational for all other indications (for example, laryngo-tracheal papillomatosis) due to insufficient evidence in the peer-reviewed literature.'

Related NICE guidance

There is currently no NICE guidance related to this procedure.

Specialist Advisers' opinions

Specialist advice was sought from consultants who have been nominated or ratified by their Specialist Society or Royal College. The advice received is their individual opinion and does not represent the view of the society.

IP overview: Radiofrequency cold ablation for respiratory papillomatosis
Page 17 of 24

Neil Bateman, Michael Kuo and Gavin A J Morrison (British Association of Paediatric Otolaryngologists), Benjamin Hartley (British Association of Otorhinolaryngologists, Head and Neck Surgeons [ENT UK]).

- All Specialist Advisers have never performed the procedure.
- Two Specialist Advisers considered the procedure to be definitely novel and of uncertain safety and efficacy. One of the two Specialist Advisers considered it to fall between a minor change in technique with equipment that is well established for other areas and a new procedure. Two other Specialist Advisers considered it to be a minor variation of an existing procedure, which is unlikely to alter the procedure's safety and efficacy.
- CO₂ laser, microdebridement, potassium titanyl phosphate laser (KTP laser) and cold steel excision would be comparators to the procedure.
- Theoretical adverse events include laryngeal or airway scarring, with airway stenosis and dysphonia as possible consequences of scarring to the larynx, bleeding and inadequate reduction in the number and size of papillomas, leading to inability to maintain a safe airway.
- One Specialist Adviser was concerned about safety of the procedure to voice (quality) and airway (patency). One Specialist Adviser noted that it is very difficult, if not impossible, to measure scarring objectively.
- Key efficacy outcomes include reduction of the number or frequency of microlaryngoscopy procedures required to maintain a safe airway and achievement of good voice quality. Other efficacy outcomes are endoscopic and photographic evidence of ablation of papillomatosis and establishment of an airway macroscopically free of papillomatosis.
- Uncertainty remains about whether the treatment holds advantages over the
 current gold standard treatments. It might theoretically do so, because the low
 temperature could avoid collateral tissue damage and the haemostatic
 properties may mean no bleeding and so less risk of inadvertent spread of the
 virus to more distal airway sites.
- Training to use the device, including surgeon education with mentoring and support, is needed.
- All Specialist Advisers thought that this procedure would have a minor impact on the NHS.
- One Specialist Adviser thought that this procedure should be confined to larger units such as a university type tertiary centre. He added that it will not be easy to establish any level 1 or even good level 2 evidence because recurrent respiratory papillomatosis is too infrequent and surgical trials in this area are fraught with difficulty. He emphasised the usefulness of more clinical case series, comparing results with other treatments. Another Specialist Adviser also noted that respiratory papillomatosis is a relatively uncommon condition and therefore appropriately powered trials may be difficult to establish.

Patient Commentators' opinions

NICE's Patient and Public Involvement Programme was unable to gather patient commentary for this procedure.

Issues for consideration by IPAC

 One of the studies included in table 2 of this overview is a Chinese language paper. The reason for inclusion is the report of minor scarring around the ablated tissues and appearance of respiratory papillomas at another location, which have not been reported by other studies.

References

- She CP, Zhang QF and Cheng CJ (2011) Coblation treatment for laryngeal papilloma in adult [Chinese]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chinese Journal of Otorhinolaryngology Head and Neck Surgery 46(4) 336–338
- 2. Carney AS, Evans AS, Mirza S and Psaltis A (2010) Radiofrequency coblation for treatment of advanced laryngotracheal recurrent respiratory papillomatosis. Journal of Laryngology and Otology 124(5) 510–514
- Peters G, McLaughlin K and Nuss DW (2011) Treatment of nasopharyngeal papillomatosis with coblation: a case series. International Forum of Allergy and Rhinology 1(5) 405–408
- 4. Timms MS, Bruce IA and Patel NK (2007) Radiofrequency ablation (coblation): A promising new technique for laryngeal papillomata. Journal of Laryngology and Otology 121(1) 28–30
- Psaltis A. and Carney AS (2003) The use of radiofrequency ablation in the treatment of tracheal papillomatosis: A case report. Australian Journal of Otolaryngology 6(2) 86–88
- 6. Rachmanidou A. and Modayil PC (2011) Coblation resection of paediatric laryngeal papilloma. Journal of Laryngology and Otology 125(8) 873–876

Appendix A: Additional papers on radiofrequency cold ablation for respiratory papillomatosis

There were no additional papers identified.

Appendix B: Related NICE guidance for radiofrequency cold ablation for respiratory papillomatosis

There is currently no NICE guidance related to this procedure.

Appendix C: Literature search for radiofrequency cold ablation for respiratory papillomatosis

Database	Date searched	Version/files
Cochrane Database of	28/03/12	Issue 3 of 12, Mar 2012
Systematic Reviews – CDSR		
(Cochrane Library)		
Database of Abstracts of	28/03/12	-
Reviews of Effects – DARE		
(CRD website)		
HTA database (CRD website)	28/03/12	-
Cochrane Central Database of	28/03/2012	Issue 3 of 12, Mar 2012
Controlled Trials – CENTRAL		
(Cochrane Library)		
MEDLINE (Ovid)	28/03/12	1946 to March Week 2 2012
MEDLINE In-Process (Ovid)	28/03/12	<march 2012<="" 27,="" td=""></march>
EMBASE (Ovid)	28/03/12	1980 to 2012 Week 12
CINAHL (NLH Search 2.0/)	28/03/12	1981-present

Trial sources searched on 28/03/2012

- Current Controlled Trials metaRegister of Controlled Trials mRCT
- Clinicaltrials.gov
- National Institute for Health Research Clinical Research Network Coordinating Centre (NIHR CRN CC) Portfolio Database

Websites searched

- National Institute for Health and Clinical Excellence (NICE)
- Food and Drug Administration (FDA) MAUDE database
- French Health Authority (FHA)
- Australian Safety and Efficacy Register of New Interventional Procedures Surgical (ASERNIP – S)
- Australia and New Zealand Horizon Scanning Network (ANZHSN)
- Conference search
- · General internet search

The following search strategy was used to identify papers in MEDLINE. A similar strategy was used to identify papers in other databases.

- 1 Papilloma/
- 2 Papillom*.tw.
- 3 RRP.tw.
- 4 JORRP.tw.
- 5 AORRP.tw.
- 6 Papillomavirus Infections/
- 7 Laryngeal Neoplasms/
- 8 (Laryng* adj3 (neoplasm* or cancer* or carcinoma* or adenocarcinom* or tumour* or

tumor* or malignan*)).tw. 9 or/1-8 Cryosurgery/ 10 (cryosury* or cryoablat* or cryotherap* or coblat*).tw. 11 ((Cold* or control* or radiofreq*) adj3 ablat*).tw. 12 13 radiofreq*.tw. 14 RF.tw. 15 RFA.tw. 16 (coblat* adj3 radiofreq*).tw. 17 Debulk*.tw. 18 Ablation Techniques/ (ablat* adj3 techniq*).tw. 19 20 Debridement/is [Instrumentation] 21 debride*.tw. 22 (plasma* adj3 wand*).tw. 23 or/10-22 24 9 and 23 Animals/ not Humans/ 25 26 24 not 25